Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes

scientific article published on December 2006

Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/01.TP.0000250712.12389.3D
P932PMC publication ID2952504
P698PubMed publication ID17198247
P5875ResearchGate publication ID6603098

P50authorThomas E. StarzlQ1248240
Ron ShapiroQ59747328
John Julian FungQ61476062
Ngoc J ThaiQ61826131
Amit BasuQ96123399
Henkie P TanQ114340592
Amadeo MarcosQ115134365
P2093author name stringAkhtar Khan
Deanna Blisard
Kusum Tom
P2860cites workHistory of clinical transplantationQ24596303
Acquired immunologic tolerance: with particular reference to transplantationQ33567138
Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantationQ34201121
Antigen localization and migration in immunity and toleranceQ34239865
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or CampathQ34304820
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virusQ34359751
Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapyQ34561556
Transplantation tolerance from a historical perspectiveQ34572212
The impact of Campath 1H induction in adult liver allotransplantationQ38514430
Tolerogenic immunosuppression for organ transplantationQ41116219
Pancreatic transplantation at the University of PittsburghQ41785260
Preliminary experience with campath 1H (C1H) in intestinal and liver transplantationQ44419266
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.Q44461489
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).Q44514934
Campath-1H in renal transplantation: The University of Wisconsin experience.Q45092670
Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantationQ46478191
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.Q46485560
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoringQ46670432
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term resultsQ46702767
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppressionQ46816120
Intestinal transplantation for short bowel syndrome and gastrointestinal failure: current consensus, rewarding outcomes, and practical guidelines.Q53257876
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipientsQ61651688
Specificity of monoclonal antibody Campath-1Q70213447
Tolerance for organ recipients: a clash of paradigmsQ79145851
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectpancreasQ9618
P304page(s)1621-1624
P577publication date2006-12-01
P1433published inTransplantationQ15730500
P1476titleAlemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes
P478volume82

Reverse relations

cites work (P2860)
Q42943652Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin
Q39991648Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation?
Q37425990Immunosuppression and rejection in human hand transplantation
Q38162892Immunosuppression for pancreas transplantation with an emphasis on antibody induction strategies: review and perspective
Q37738864Immunosuppression in simultaneous pancreas-kidney transplantation: progress to date
Q40956691Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression
Q38558078Opportunistic infections complicating solid organ transplantation with alemtuzumab induction
Q83893794Pancreas transplantation
Q34699278Pancreas transplantation: The Wake Forest experience in the new millennium
Q35128345Pancreas transplantation: lessons learned from a decade of experience at Wake Forest Baptist Medical Center
Q35963432Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation
Q46340832The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation

Search more.